SEC Form 4 · accession 0001193125-26-380152
Amylyx Pharmaceuticals, Inc. · AMLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Firestone
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2026 | M | 25,000 | $1.76 | A | 91,900 | D | |
| Common Stock | Aug 31, 2026 | M | 25,000 | $5.05 | A | 116,900 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.76 | Aug 31, 2026 | M | 25,000 | D | — | Jun 5, 2034 | Common Stock | 25,000 | 0 | D |
| Stock Option (right to buy)F1 | $5.05 | Aug 31, 2026 | M | 25,000 | D | — | Jun 4, 2035 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1This option is fully vested and exercisable.